Having trouble accessing articles? Reset your cache.

Modis deal bolsters Zogenix’s late-stage, rare disease pipeline

With its acquisition of Modis, Zogenix will need to blaze a regulatory trail for Modis’ thymidine kinase 2 deficiency program while still pushing its own Dravet syndrome therapy through regulatory approval.

Zogenix Inc. (NASDAQ:ZGNX) said Monday it will acquire rare mitochondrial disease company Modis Therapeutics Inc. (Oakland, Calif.) for $250 million, comprising $175 million

Read the full 533 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers